Enanta loses patent infringement action against Pfizer as UPC rules patent invalid

PFE•2026-10-29

The UPC ruled that Enanta’s patent was invalid and its infringement action against Pfizer was unfounded, according to a securities filing.

1. UPC ruling

Enanta Pharmaceuticals said in a securities filing that the UPC ruled its ’265 patent invalid and determined its patent infringement action against Pfizer was unfounded.

Enanta loses patent infringement action against Pfizer as UPC rules patent invalid

1. UPC ruling

Related News

Equities and bond yields dip with AI jitters and economic data in focus

Cytek Biosciences participates in UBS and Stephens investor conferences

Leader’s Advantage raises IPO gross proceeds to $156.5 million after over-allotment exercise

Bristow Group declares quarterly cash dividend of $0.125 per share

Federated Hermes AUM falls 3% quarter-on-quarter to $884.4 billion